Study #SWOGS1802
SWOGS1802: Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
MD Anderson Study Status
Enrolling
Treatment Agent
Abiraterone, Bicalutamide, Degarelix, Flutamide, Goserelin Acetate, Histrelin Acetate, Leuprolide Acetate, Nilutamide, Triptorelin, Docetaxel, Prednisone
Description
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Study phase:
Phase III
Physician name:
Brian Chapin
Department:
Urology
For general questions about clinical trials:
1-855-939-4993
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.